Jens Brønnum S.
- Country
- Denmark
- Department
- Dept Cardiology
Research Overview
- Evaluation of Hydralazine Hydrochloride, Isosorbide Dinitrate, and Metformin Hydrochloride in Chronic Heart Failure with Reduced Ejection Fraction
- Evaluation of Carvedilol, Metoprolol Tartrate, and Bisoprolol Fumarate in Post-Myocardial Infarction Patients with Preserved Ejection Fraction
- A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction
Data & Insights
Has run more than one trial at 15 of 142 partner sites.
Specializations
Coronary artery disease and atherosclerotic cardiovascular disease
Jens Brønnum Schou’s clinical research activity is centered on atherosclerotic cardiovascular disease, with a strong focus on preventing major ischemic events in people with high cardiovascular risk, established vascular disease, and primary prevention populations.
- Myocardial infarction
- Acute coronary syndrome
- Primary prevention of atherosclerotic cardiovascular disease
- Elevated lipoprotein(a)
His work also extends to therapies aimed at reducing recurrent coronary events and limiting progression of atherosclerotic heart and blood vessel disease.
Heart failure and cardiometabolic risk
Another major therapeutic area is heart failure, especially chronic heart failure with reduced ejection fraction and prevention of worsening cardiac outcomes in patients with impaired ventricular function.
- Heart failure
- Chronic heart failure with reduced ejection fraction
- Prevention of heart failure
- Hypertension
His clinical interests include treatment strategies for reducing heart failure hospitalization, cardiovascular death, and risk linked to uncontrolled blood pressure and metabolic burden.
Atrial fibrillation and thromboembolic prevention
Jens Brønnum Schou is also involved in research on atrial fibrillation, with emphasis on preventing stroke and systemic embolism in patients with arrhythmia-related thromboembolic risk.
- Atrial fibrillation
- Prevention of stroke or systemic embolism in atrial fibrillation
- Cardioembolic events
- Major bleeding
This area reflects a sustained interest in balancing protection from embolic complications with bleeding-related safety considerations.
Lipid modification and residual cardiovascular risk
His portfolio includes therapies targeting residual risk driven by abnormal lipid profiles, particularly in patients whose standard treatment remains insufficient to control cardiovascular risk.
- Low-density lipoprotein cholesterol reduction
- Lipoprotein(a) lowering
- Obesity or overweight with ASCVD
- High-risk preventive lipid therapy
His research interests also extend to emerging approaches for reducing major adverse cardiovascular events in patients with persistent atherothrombotic risk.
Infectious disease and vaccination
Beyond cardiovascular medicine, Jens Brønnum Schou is involved in clinical research on community-acquired pneumonia and meningococcal immunization, covering both treatment-related and preventive infectious disease domains.
- Community-acquired pneumonia
- Meningococcal vaccination
- Immune response
- Infection prevention
These activities add an immunologic and anti-infective dimension to his broader clinical research profile.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.